Cargando…

Craniosynostosis affects the majority of mucopolysaccharidosis patients and can contribute to increased intracranial pressure

BACKGROUND: The mucopolysaccharidoses are multisystem lysosomal storage diseases characterized by extensive skeletal deformities, including skull abnormalities. The objective of this study was to determine the incidence of craniosynostosis in the different mucopolysaccharidosis (MPS) types and its c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oussoren, Esmee, Mathijssen, Irene M. J., Wagenmakers, Margreet, Verdijk, Rob M., Bredero-Boelhouwer, Hansje H., van Veelen-Vincent, Marie-Lise C., van der Meijden, Jan C., van den Hout, Johanna M. P., Ruijter, George J. G., van der Ploeg, Ans T., Langeveld, Mirjam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326980/ https://www.ncbi.nlm.nih.gov/pubmed/30083803 http://dx.doi.org/10.1007/s10545-018-0212-1

Ejemplares similares

Orofacial abnormalities in mucopolysaccharidosis and mucolipidosis type II and III: A systematic review
por: de Bode, Chiel J., et al.
Publicado: (2022)

Mucolipidosis type III, a series of adult patients
por: Oussoren, Esmee, et al.
Publicado: (2018)

Modeling cartilage pathology in mucopolysaccharidosis VI using iPSCs reveals early dysregulation of chondrogenic and metabolic gene expression
por: Broeders, M., et al.
Publicado: (2022)

Severe tracheal and bronchial collapse in adults with type II mucopolysaccharidosis
por: Rutten, M., et al.
Publicado: (2016)

Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
por: Brands, Marion M. M. G., et al.
Publicado: (2012)

Using Out-of-Batch Reference Populations to Improve Untargeted Metabolomics for Screening Inborn Errors of Metabolism
por: Bongaerts, Michiel, et al.
Publicado: (2020)

Brain and ventricular volume in patients with syndromic and complex craniosynostosis
por: de Jong, T., et al.
Publicado: (2011)

Cerebral cortex maldevelopment in syndromic craniosynostosis
por: Wilson, Alexander T, et al.
Publicado: (2021)

Sagittal Craniosynostosis: Comparing Surgical Techniques Using 3D Photogrammetry
por: Abdel-Alim, Tareq, et al.
Publicado: (2023)

Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II
por: Catalano, Fabio, et al.
Publicado: (2023)

Improvement in Sleep Architecture is associated with the Indication of Surgery in Syndromic Craniosynostosis
por: de Goederen, Robbin, et al.
Publicado: (2019)

Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase
por: Brands, Marion M, et al.
Publicado: (2013)

A Generic Assay to Detect Aberrant ARSB Splicing and mRNA Degradation for the Molecular Diagnosis of MPS VI
por: Broeders, Mike, et al.
Publicado: (2020)

Guideline for Care of Patients With the Diagnoses of Craniosynostosis: Working Group on Craniosynostosis
por: Mathijssen, Irene M.J.
Publicado: (2015)

Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease
por: Ernst, Martijn P.T., et al.
Publicado: (2020)

Long-term benefits of physical activity in adult patients with late onset Pompe disease: a retrospective cohort study with 10 years of follow-up
por: Ismailova, Gamida, et al.
Publicado: (2023)

A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses
por: Langereis, Eveline J., et al.
Publicado: (2015)

Augmented reality navigation for minimally invasive craniosynostosis surgery: a phantom study
por: Thabit, Abdullah, et al.
Publicado: (2022)

Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB
por: Meijer, O. L. M., et al.
Publicado: (2016)

Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Updated Guideline on Treatment and Management of Craniosynostosis
por: Mathijssen, Irene M.J.
Publicado: (2021)

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients
por: van der Meijden, Jan C., et al.
Publicado: (2018)

A diffusion tensor imaging analysis of white matter microstructures in non-operated craniosynostosis patients
por: de Planque, C. A., et al.
Publicado: (2022)

Association of Muscle Strength and Walking Performance in Adult Patients With Pompe Disease
por: Favejee, Marein M, et al.
Publicado: (2018)

Identification of a novel variant of the ciliopathic gene FUZZY associated with craniosynostosis
por: Barrell, William B., et al.
Publicado: (2021)

Gain-of-Function Mutations in ZIC1 Are Associated with Coronal Craniosynostosis and Learning Disability
por: Twigg, Stephen R.F., et al.
Publicado: (2015)

Introduction to Updated Guideline on Treatment and Management of Craniosynostosis
por: Mathijssen, Irene M.J.
Publicado: (2021)

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
por: Wraith, J. Edmond, et al.
Publicado: (2007)

Pathway to diagnosis and burden of illness in mucopolysaccharidosis type VII – a European caregiver survey
por: Morrison, Alexandra, et al.
Publicado: (2019)

Mild disease course of SARS-CoV-2 infections and mild side effects of vaccination in Pompe disease: a cohort description
por: Ismailova, G., et al.
Publicado: (2022)

Guideline on Treatment and Management of Craniosynostosis: Patient and Family Version
por: Faasse, Mariët, et al.
Publicado: (2023)

Is Cortical Complexity Development Affected By Syndromic Craniosynostosis?
por: Wilson, Alexander T., et al.
Publicado: (2020)

Retrospective evaluation of the Dutch pre‐newborn screening cohort for propionic acidemia and isolated methylmalonic acidemia: What to aim, expect, and evaluate from newborn screening?
por: Haijes, Hanneke A., et al.
Publicado: (2019)

Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Identification of Intragenic Exon Deletions and Duplication of TCF12 by Whole Genome or Targeted Sequencing as a Cause of TCF12‐Related Craniosynostosis
por: Goos, Jacqueline A.C., et al.
Publicado: (2016)

Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review
por: Ditters, Imke A. M., et al.
Publicado: (2023)

The effect of earthquakes on the housing market and the quality of life in the province of Groningen, the Netherlands
por: Boelhouwer, Peter, et al.
Publicado: (2018)

Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease
por: Schaaf, Gerben J., et al.
Publicado: (2015)

Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don’t
por: van der Veen, Sanne Jolien, et al.
Publicado: (2022)

Cranial shape comparison for automated objective 3D craniosynostosis surgery planning
por: Tolhuisen, Manon L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kabktlff0mjqlrp632b8boib20